Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A1 | P53985 | 15/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 9/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.52 |
| ▸ | SLC16A7 | O60669 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 3/20 | 0.36 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7006901 | 0.82 | SLC16A1 (0.59) | SLC16A1CYP2C9CYP3A4SLC16A7 | |
| SCHEMBL7005962 | 0.76 | KMT2A (0.42) | SLC16A1CYP2C9CYP3A4BRD4PTGER4 | |
| SCHEMBL5805048 | 0.72 | SLC16A1 (0.47) | SLC16A1CYP2C9CYP3A4SLC16A7 | |
| SCHEMBL7005645 | 0.72 | SLC16A1 (0.47) | SLC16A1CYP2C9CYP3A4SLC16A7 | |
| SCHEMBL7007701 | 0.71 | SLC16A1 (0.51) | SLC16A1CYP2C9CYP3A4 | |
| SCHEMBL4920834 | 0.69 | SLC16A1 (0.44) | SLC16A1CYP2C9CYP3A4SLC16A7 | |
| SCHEMBL7004524 | 0.67 | LMNA (0.40) | SLC16A1CYP2C9CYP3A4 | |
| SCHEMBL7008632 | 0.66 | BRD4 (0.41) | CYP3A4BRD4 | |
| SCHEMBL7010063 | 0.66 | SLC16A1 (0.69) | SLC16A1CYP2C9CYP3A4SLC16A7 | |
| SCHEMBL4920817 | 0.65 | SLC16A1 (0.44) | SLC16A1CYP2C9CYP3A4SLC16A7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1107973-B1 | NOVEL THIENO[2,3-d]PYRIMIDINEDIONES, PROCESS FOR THEIR PREPARATION AND USE THEREOF IN THERAPY | ASTRAZENECA AB (SE) | 2003-11-05 | — | — | EP | disclosed |
| US-6300334-B1 | DRUGS FOR TREATMENT OF RESPIRATORY SYSTEM DISORDERS | ASTRAZENECA AB (SE) | 2001-10-09 | — | — | US | disclosed |
| EP-1107973-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000012514-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2000-03-09 | — | — | WO | disclosed |